Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Latest news articles

Added 23 days ago Drug news

FDA accepts priority review for Xarelto (rivaroxaban) in venous thromboembolism- Janssen

The FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban), from Janssen, to include...

Added 26 days ago Drug news

FDA approves Bevyxxa (betrixaban) to treat venous thromboembolism (VTE).-Portola Pharmaceuticals Inc,

Portola Pharmaceuticals Inc. announced the FDA has approved Bevyxxa (betrixaban), the first and only anticoagulant for hospital and extended duration...

Added 4 months ago Drug news

Results of phase III EINSTEIN CHOICE show patients with venous thromboembolism taking Xarelto (rivaroxaban) have reduced bleeding events- Janssen Pharma

Janssen Pharmaceuticals has announced new Phase III results from EINSTEIN CHOICE showing patients with venous thromboembolism (VTE) taking Xarelto (rivaroxaban),...

Search all news articles for Pulmonary heart disease
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)


Guidelines

Guideline on aspects of cancer-related venous thrombosis

The objective of this guideline is to provide healthcare professionals with clear guidance on the prevention and management of venous...

Added 1 year ago

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular...

Added 1 year ago

Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management

The aim of this guideline is to provide information, based on clinical evidence where available, regarding the immediate investigation and...

Added 2 years ago

Search all guidelines for Pulmonary heart disease
 

Journal articles

Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) ...

Added 1 month ago

Edoxaban: A direct oral anticoagulant.

Purpose: The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and ...

Added 1 month ago

Selexipag: A Review in Pulmonary Arterial Hypertension.

Selexipag (Uptravi®) is an orally active, first-in-class, selective prostacyclin IP receptor agonist. Selexipag was approved recently in the EU for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients ...

Added 4 months ago

Search all journal articles for Pulmonary heart disease
 
David Warriner

Dr David R Warriner is currently a Cardiology Registrar practising in South Yorkshire. Dr Warriner's clinical and research interests include heart failure, exercise physiology, physiological modelling, sports medicine and medical education. In his free time, Dr Warriner loves reading ... Read more

What is Overdiagnosis?

Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.